RSO-021 Market Summary

Key Factors Driving RSO-021 Growth

1. High unmet need in malignant pleural mesothelioma and MPE

MPE is a major complication of advanced cancers and is particularly prevalent in pleural mesothelioma; a recent publication notes that approximately 90% of pleural mesothelioma patients present with MPE. Existing management is primarily palliative, including repeated drainage and indwelling pleural catheters, leaving a significant need for treatments that can control the underlying malignancy. RSO-021 is designed to treat the malignant disease directly within the pleural cavity, giving it a potentially differentiated position if efficacy is confirmed.

2. First-in-class PRX3 mechanism provides a novel therapeutic approach

RSO-021 is the clinical formulation of thiostrepton, which covalently inhibits mitochondrial PRX3. Tumor cells generate high levels of reactive oxygen species (ROS) and rely on antioxidant systems such as PRX3 to survive this oxidative stress. Inhibiting PRX3 increases mitochondrial oxidative stress and can trigger tumor-cell death while potentially sparing normal cells. Preclinical work demonstrated that genetic deletion of PRX3 impaired mesothelioma bioenergetics and tumor growth, strengthening PRX3 as a potential cancer target.

3. Encouraging Phase I clinical efficacy signals

The most important growth catalyst is the emerging human efficacy evidence. In the Phase I MITOPE study, 15 patients were treated; the recommended/maximum tolerated dose was established at 90 mg weekly, and systemic exposure was minimal following intrapleural administration. Among 10 evaluable patients, disease control was 70%, while one patient achieved a 59% reduction in mesothelioma target lesions. Median PFS at the 90-mg dose was 5.7 months in the ASCO-reported dataset.

More mature 2026 peer-reviewed data reported 67% disease control at 12 weeks in the 90-mg cohort, with one partial response lasting through week 30. Median pleural-fluid drainage fell from approximately 700 mL/week before treatment to 175 mL/week at treatment discontinuation, suggesting potential symptomatic as well as antitumor benefit.

4. Phase II development broadens the addressable population

RSO-021 has progressed into the Phase II dose-expansion portion of MITOPE (NCT05278975). The study is evaluating patients with newly diagnosed mesothelioma, previously treated/relapsed mesothelioma, local metastatic lung disease with MPE, and MPE associated with breast, ovarian and non-small-cell lung cancers, including combination treatment with systemic paclitaxel. This broad indication strategy could substantially increase the eventual addressable population if efficacy is demonstrated across cohorts.

5. Potential for combination with immuno-oncology therapies

RSO-021 may have utility beyond monotherapy. 2026 AACR research reported that RSO-021/thiostrepton altered immune phenotypes, while a mouse mesothelioma model showed complete tumor reduction in 6/6 animals when thiostrepton was combined with anti-PD-1/anti-CTLA-4 therapy, compared with 30% tumor reduction with thiostrepton alone. These are preclinical findings—not clinical proof—but they support exploration of RSO-021 in combination with immune-checkpoint inhibitors and potentially other systemic therapies.

RSO-021 Recent Developments

In April 2026, RS Oncology indicated that it would present new RSO-021 data at AACR 2026 and participate in the AACR Oncology Industry Partnering Event. This indicates active business-development outreach, although I did not identify a publicly announced licensing, co-development or commercial partnership resulting from that event.

“RSO-021 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of RSO-021 for potential indication like Malignant pleural effusion, Malignant-mesothelioma, Solid tumours, Ovarian cancer, and Peritoneal cancer in the 7MM. A detailed picture of RSO-021’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the RSO-021 for potential indications. The RSO-021 market report provides insights about RSO-021’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current RSO-021 performance, future market assessments inclusive of the RSO-021 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of RSO-021 sales forecasts, along with factors driving its market.

RSO-021 Drug Summary

RSO-021 is an investigational, first-in-class anticancer therapy developed by RS Oncology and formulated from thiostrepton, a naturally occurring sulfur-rich cyclic oligopeptide, for the treatment of malignant pleural effusion (MPE) associated with malignant pleural mesothelioma and other advanced solid tumors. RSO-021 is a covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), a key antioxidant enzyme that helps tumor cells neutralize mitochondrial hydrogen peroxide and survive oxidative stress. By covalently binding to active-site cysteine residues of PRX3, RSO-021 inhibits its peroxidase activity, increases mitochondrial oxidative stress, and promotes tumor-cell death. The drug is administered locally by intrapleural infusion through an indwelling catheter, allowing direct exposure of pleural tumors and malignant pleural fluid to the therapy. RSO-021 has demonstrated antitumor activity in preclinical models and has progressed through Phase I clinical evaluation, with Phase II development exploring its use as monotherapy and in combination with paclitaxel in patients with MPE arising from mesothelioma and other solid tumors, including lung, breast, and ovarian cancers. The report provides RSO-021’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the RSO-021 Market Report

The report provides insights into:

• A comprehensive product overview including the RSO-021 MoA, description, dosage and administration, research and development activities in potential indication like Malignant pleural effusion, Malignant-mesothelioma, Solid tumours, Ovarian cancer, and Peritoneal cancer.
• Elaborated details on RSO-021 regulatory milestones and other development activities have been provided in RSO-021 market report.
• The report also highlights RSO-021‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The RSO-021 market report also covers the patents information, generic entry and impact on cost cut.
• The RSO-021 market report contains current and forecasted RSO-021 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The RSO-021 market report also features the SWOT analysis with analyst views for RSO-021 in potential indications.

Methodology

The RSO-021 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RSO-021 Analytical Perspective by DelveInsight

• In-depth RSO-021 Market Assessment

This RSO-021 sales market forecast report provides a detailed market assessment of RSO-021 for potential indication like Malignant pleural effusion, Malignant-mesothelioma, Solid tumours, Ovarian cancer, and Peritoneal cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted RSO-021 sales data uptil 2034.

• RSO-021 Clinical Assessment

The RSO-021 market report provides the clinical trials information of RSO-021 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

RSO-021 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

RSO-021 Market Potential & Revenue Forecast

• Projected market size for the RSO-021 and its key indications
• Estimated RSO-021 sales potential (RSO-021 peak sales forecasts)
• RSO-021 Pricing strategies and reimbursement landscape

RSO-021 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• RSO-021 Market positioning compared to existing treatments
• RSO-021 Strengths & weaknesses relative to competitors

RSO-021 Regulatory & Commercial Milestones

• RSO-021 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

RSO-021 Clinical Differentiation

• RSO-021 Efficacy & safety advantages over existing drugs
• RSO-021 Unique selling points

RSO-021 Market Report Highlights

• In the coming years, the RSO-021 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The RSO-021 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RSO-021’s dominance.
• Other emerging products for Malignant pleural effusion, Malignant-mesothelioma, Solid tumours, Ovarian cancer, and Peritoneal cancer are expected to give tough market competition to RSO-021 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RSO-021 in potential indications.
• Analyse RSO-021 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted RSO-021 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of RSO-021 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of RSO-021? How strong is RSO-021’s clinical and commercial performance?
• What is RSO-021’s clinical trial status in each individual indications such as Malignant pleural effusion, Malignant-mesothelioma, Solid tumours, Ovarian cancer, and Peritoneal cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RSO-021 Manufacturers?
• What are the key designations that have been granted to RSO-021 for potential indications? How are they going to impact RSO-021’s penetration in various geographies?
• What is the current and forecasted RSO-021 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of RSO-021 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to RSO-021 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is RSO-021? What is the duration of therapy and what are the geographical variations in cost per patient?